ERBB2 and breast cancer: Nowadays, the standard therapy for HER2-positive (HER2+) BC patients is a combination of anti-HER2 targeted therapy agents such as the monoclonal antibody trastuzumab (TZ), and chemotherapy (Valachis et al. 2011).